Kymera Therapeutics, Inc.

Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering the field of targeted protein degradation (TPD). The company utilizes its proprietary Pegasus™ platform to discover and develop oral small molecule degraders that harness the body's natural protein recycling machinery to selectively degrade disease-causing proteins that were previously considered undruggable. Kymera is focused on building an industry-leading pipeline of first-in-class therapeutics, primarily targeting immunological diseases and oncology. The company is headquartered in Watertown, Massachusetts, and is publicly traded on the NASDAQ.